Department of Neurosurgery, University of Florida, Gainesville, FL, USA. n
Future Oncol. 2013 Sep;9(9):1389-96. doi: 10.2217/fon.13.96.
Bevacizumab has been reported to result in increased tumor invasion when used to treat malignant glioma. We hypothesized that BMP4 would prevent diffuse tumor infiltration induced by bevacizumab for malignant glioma in a xenograft model.
Human glioblastoma (GBM) tumor cells were implanted in the striatum of immunocompromised mice. The animals were treated with bevacizumab and BMP4. Tumor growth and invasion were measured.
The bevacizumab-treated mice had increased survival compared with control animals (p = 0.02). BMP4 alone did not result in improved survival (p = 1.0). The bevacizumab (p = 0.006) and bevacizumab plus BMP4 (p = 0.006) groups demonstrated significantly decreased total tumor size compared with control. Tumor invasion was significantly decreased in the bevacizumab (p = 0.005), BMP4 (p = 0.04) alone and bevacizumab plus BMP4 (p = 0.002) groups compared with control. No synergistic effect between bevacizumab and BMP4 was observed.
Bevacizumab treatment did not result in diffuse infiltration of human GBM in a mouse xenograft model. BMP4 did have an independent favorable effect on GBM that was not synergistic with bevacizumab treatment.
已有报道称贝伐单抗用于治疗恶性神经胶质瘤时会导致肿瘤侵袭增加。我们假设 BMP4 会阻止贝伐单抗诱导的恶性神经胶质瘤异种移植模型中的弥漫性肿瘤浸润。
将人胶质母细胞瘤（GBM）肿瘤细胞植入免疫缺陷小鼠的纹状体中。对动物进行贝伐单抗和 BMP4 治疗。测量肿瘤生长和浸润。
与对照组相比，贝伐单抗治疗组的小鼠生存率提高（p = 0.02）。BMP4 单独使用不会导致生存率提高（p = 1.0）。与对照组相比，贝伐单抗（p = 0.006）和贝伐单抗加 BMP4（p = 0.006）组的总肿瘤体积明显减小。与对照组相比，贝伐单抗（p = 0.005）、BMP4 单独（p = 0.04）和贝伐单抗加 BMP4 组（p = 0.002）的肿瘤侵袭明显减少。贝伐单抗和 BMP4 之间没有协同作用。
贝伐单抗治疗并未导致人 GBM 在小鼠异种移植模型中发生弥漫性浸润。BMP4 对 GBM 有独立的有利影响，与贝伐单抗治疗无协同作用。
